Blog - Page 5540 of 5669

MondayJan 01, 2007 6:47 am

SmallCapVoice Client:Sweet Success Enterprises Inc (SWTS)

San Antonio-based Sweet Success Enterprises Inc. acquired Nestlé’s original Sweet Success™ brand and has re-launched as Fuel for Health™; an all natural product line to tap into the rapidly growing demand for all natural and self stable health and wellness beverages. Sweet Success is now available in a growing number of stores and includes select ingredients to satiate, boost energy and immunity and enhance a healthy lifestyle. Sweet Success® contracts for the production, marketing and distribution of all-natural beverages under the brand names Sweet Success® Fuel For Health™. The Sweet Success product line includes: GlucaSafe, a functional health beverage with…

MondayJan 01, 2007 6:46 am

SmallCapVoice Client: Neostem Inc. (NBS)

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies. The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their…

MondayJan 01, 2007 6:37 am

Detailed Quote for Intelligentias Inc. (ITLI)

Intelligentias, Inc. expects to become a global data-intelligence conglomerate. Using a worldwide network, we market Homeland Security products to Law Enforcement Agencies, Telcos and ISPs in order to prevent terrorism, cyber-crime, and child exploitation. Aside from Retentia, we also have a presence in other areas of the security space. Our portfolio company, Investigatia, Inc., which will be launched later in 2007, will be our data investigation company. Investigatia intends to focus on fraud, identity theft, identity authentication and verification. Our portfolio company, Interceptia, Inc., operates in Europe and the Middle East as Datakom GmbH. As our Lawful Intercept Company, Interceptia…

MondayJan 01, 2007 6:13 am

Axial Vector Engine (OTCBB: AXVC) Receives New Financing

Axial Vector Engine Corp recently announced that it was closing its private placement after receiving $2.7M from its investors at $2.00 per share. Dr. Raymond Brouzes, President and CEO of Axial Vector stated, "We are extremely pleased by the support of our shareholders who provided this very favorable financing to the company. Our development and patenting program continues full speed ahead. We will be premiering our new low cost Power Generating Technologies at the 'World Power Generation Show ' November 28 -30 in Orlando Florida." This announcement followed on the heels of their recent patent filing for their broad intellectual…

MondayJan 01, 2007 6:13 am

Immune Response (OTCBB: IMNR) Secures Partners for MS Clinical Trials

Immune Response Corporation recently announced on that it has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax, an investigational T-cell receptor peptide vaccine for the treatment of MS. Immune went on further to announce that in November they will hold a clinical trial meeting in Budapest, Hungary to discuss plans for a multi-center trial. This trial will also be a double-blind placebo control test to further investigate the viability of NeuroVax as a treatment for MS.…

MondayJan 01, 2007 6:13 am

Xechem’s (OTCBB: XKEM) Orphan Drug Status Approved for New Sickle Cell Drug

Recently, the EU approved "Orphan Drug Status" for Xechem International's sickle cell drug dubbed Niprisan, a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease. The designation covers all 25 member countries that comprise the European Union. A similar Orphan Drug Status was granted to Xechem by the U.S. Food and Drug Administration. Dr. Ramesh Pandey, Xechem's Chairman & CEO said, "Obtaining Orphan Drug status for our Sickle Cell Disease product in both the European Union and the United States brings to Xechem substantial advantages and incentives which will help facilitate approval of the drug and…

MondayJan 01, 2007 6:09 am

Positron (OTCBB: POSC) May Get a Boost from PET Scanning of Lymphoma Patients

In a recent online edition of Clinical Oncology, PET scanning is introduced for the first time as a standardized method to assess the progression of a patientâ€™s lymphoma treatment. This marks the first time that the standards have been revisited on an international scale. PET imaging, in contrast to traditional CT scanning, can discern the difference between a tumor and scar tissue left behind after a successful surgery. The efficacy of the scanning allows for a definitive diagnosis in both cases of there being no tumor or the presence of one. This will allow for greater speed in treatment for…

MondayJan 01, 2007 6:09 am

Power Air (OTCBB: PWAC) to Commercialize it Zinc Air Fuel Generator

E-mail Power Air (OTCBB: PWAC) recently signed a Memorandum of Understanding (MOU) with Autobotics Inc regarding the recycling of zinc. Under the terms of the agreement, the two companies will work together to manufacture and recycle the spent fuel from the first indoor generator. Power Air then intends to market the zinc fueled generator worldwide as a no emission backup generator for both indoor and outdoor use. The fact that the generator can operate with zero emissions indoor is important to the consumer market. Just within the past few months, vicious winter storms have struck both the Northwest and the…

MondayJan 01, 2007 6:05 am

CompuMed (OTCBB: CMPD) Could Boost Revenue with Grants

The FCC has announced a two-year pilot program that would fund up to 85% of the costs for the design, construction and use of dedicated broadband networks in order to expand the availability and use of tele-health and tele-medicine, particularly in rural areas. Unlike existing rural health subsidy programs, this new program specifically contemplates that major urban health centers would be eligible to participate and receive funding if they include rural health care providers in the network. One of the companies at the forefront of tele-medicine is CompuMed. CompuMed has been a leading pioneer of tele-medicine, establishing one of…

MondayJan 01, 2007 6:04 am

ORAMED PHARMACEUTICL (OTC BB:ORMP.OB)

Understanding diabetes and the role of insulin Diabetes is a common condition in which the amount of glucose (sugar) in the blood is too high because the body is unable to use it properly. This is because the body´s method of converting glucose into energy is not working as it should. Diabetes can lead to serious complications, such as heart disease, strokes, amputations, eye and kidney damage, and premature death. In developing countries, diabetes is the fourth-ranking cause of death. Without question, diabetics have been slaves to syringes long enough. An effective insulin capsule has been long awaited by diabetics…

Site Search

Company Search

SmallCapVoice Client:Sweet Success Enterprises Inc (SWTS)

SmallCapVoice Client: Neostem Inc. (NBS)

Detailed Quote for Intelligentias Inc. (ITLI)

Axial Vector Engine (OTCBB: AXVC) Receives New Financing

Immune Response (OTCBB: IMNR) Secures Partners for MS Clinical Trials

Xechem’s (OTCBB: XKEM) Orphan Drug Status Approved for New Sickle Cell Drug

Positron (OTCBB: POSC) May Get a Boost from PET Scanning of Lymphoma Patients

Power Air (OTCBB: PWAC) to Commercialize it Zinc Air Fuel Generator

CompuMed (OTCBB: CMPD) Could Boost Revenue with Grants

ORAMED PHARMACEUTICL (OTC BB:ORMP.OB)

Market Basics

Newsletter Publishers

Public Companies